VAIA
YMAB

Virtus Alternative Investment Advisers’s Y-mAbs Therapeutics YMAB Stock Holding History

Virtus Alternative Investment Advisers’s Portfolio YMAB Stock Details YMAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-147
Closed -$7K – 233
2020
Q4 		$7K Sell
147
-654
-82% -$30.3K 0.1% 155
2020
Q3 		$33K Buy
801
+289
+56% +$11.5K 0.61% 30
2020
Q2 		$22K Buy
+512
New +$19.4K 0.34% 52

Other funds holding YMAB

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return

Virtus Alternative Investment Advisers's YMAB Position: Q1 2021 in Review

Virtus Alternative Investment Advisers sold out of Y-mAbs Therapeutics (YMAB) in Q1 2021, closing a stake of 147 shares — an estimated $7K sold.

Virtus Alternative Investment Advisers first reported a position in YMAB in Q2 2020 and held it in 3 quarters. The position peaked at $33K in Q3 2020. 117 funds tracked by Wall St. Rank hold YMAB as of Q1 2021.

  • Virtus Alternative Investment Advisers reported no remaining Y-mAbs Therapeutics position as of Q1 2021 after selling out during the quarter.
  • Virtus Alternative Investment Advisers sold 147 Y-mAbs Therapeutics shares in Q1 2021, an estimated $7K.
  • Virtus Alternative Investment Advisers first reported a position in Y-mAbs Therapeutics in Q2 2020 and held it in 3 quarters.
  • Virtus Alternative Investment Advisers's Y-mAbs Therapeutics position peaked at $33K in Q3 2020.
  • 117 funds tracked by Wall St. Rank held Y-mAbs Therapeutics as of Q1 2021.

Based on Virtus Alternative Investment Advisers's 13F filing for Q1 2021.